Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: Modeling of sustained antibody responses☆

Ten‐year immune persistence and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in females vaccinated at 15–55 years of age

“…Two different mixed effects models were used, piecewise and modified power‐law (Fraser) 19. The piecewise model used a linear function in which the data were fitted on four non‐overlapping time intervals (with breakpoints at months 7, 12, 21, and 48) that corresponded to the observed decay of humoral antibodies.…”

Antibody persistence and T-cell balance: Two key factors confronting HIV vaccine development

“…Fortunately, models have been developed that predict long-term zone 3 decay curves based on data obtained in zones 1 and 2 and in early zone 3. Examples of the mathematical models and their predictions can be found elsewhere (59)(60)(61). A comparative evaluation of the three most current mathematical models for single datasets can be found in a study by Andraud et al (67).…”

“…By contrast, anti-HPV binding titers clearly enter zone 2 and are predicted to persist for decades. The contrast between the two vaccines is even more striking when it is considered that the RV144 V1/V2 curve is seropositivity, whereas the anti-HPV curve is titers, where the vast majority of vaccinees remain seropositive for decades (60). The t 1/2 estimate for the putatively protective IgG anti-V1/V2 response in the RV144 trial is estimated to be from 11.7 to 23.7 wk depending on the assay antigen (26).…”

“…In B, the same data are plotted on a time scale more representative of durable antibody responses elicited by the licensed vaccines in Table 2. The green line represents data for the persistence of anti-HPV antibody titers modeled by a modified power law in a study by David et al (60). The data in A and B were plotted from tables in the study by Yates et al (26) or digitized from the original publications (23,30,60) using the commercially available software DigitizeIt (www.…”

Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: End-of-study analysis of a Phase III randomized trial

“…Modeling of anti-HPV-16 and -18 antibody dynamics following vaccination may be valuable in predicting duration of vaccine-induced HPV immunogenicity beyond the empirical follow-up. 5,6 Predictive modeling has been applied to estimate the persistence of antibodies induced following hepatitis A and B vaccination. [7][8][9] The aims of the end-of-study analysis reported here are: 1) to evaluate the serum antibody response of the HPV-16/18 and the HPV-6/11/16/18 vaccines measured by pseudovirion-based neutralization assay (PBNA) and enzyme-linked immunosorbent assay (ELISA) through Month 60 (i.e., 54 months after completion of the full vaccination series); 2) to predict the long-term persistence of vaccine-induced anti-HPV-16 and anti-HPV-18 antibody responses (PBNA, ELISA) in subjects receiving a full series of vaccination by applying statistical models to antibody levels measured during the 5-y study duration; and 3) to evaluate safety up to Month 60.…”